IGM Biosciences Inc (NAS:IGMS)
$ 9.22 -0.07 (-0.75%) Market Cap: 544.20 Mil Enterprise Value: 295.49 Mil PE Ratio: 0 PB Ratio: 3.40 GF Score: 36/100

IGM Biosciences Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2024 / 07:15PM GMT
Release Date Price: $11.07 (-5.02%)
Eric Joseph JPMorgan Chase;Co.;Analyst

&-

Good morning. I'm Eric Joseph, senior biotech analyst with JPMorgan. And our next presenting company is IGM Biosciences presenting on behalf of the company's CEO, Fred Schwarzer. (Operator Instructions) With that, Fred, thanks for joining us.

Fred Schwarzer IGM Biosciences
Inc. - CEO

Thanks Eric, and thanks very much to JPMorgan for the opportunity to present. We greatly appreciate it. So this is our forward-looking statement disclosure. We will be making some forward-looking statements in this presentation. And you know, there are a whole bunch of risks out there and things don't always work out exactly the way we hope. And so we'd like to direct you to all of the risk factors that are in our filings with the SEC to describe some of those risks.

As a -- big picture overview, we believe that we are the global leaders in the development of IgM antibodies. As far as we know, we represent the only significant commercial effort anywhere in biotech or pharma that's focused on IgM

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot